UK Markets close in 5 hrs 50 mins

Biomea Fusion, Inc. (BMEA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
32.35+1.64 (+5.34%)
At close: 04:00PM EDT
31.09 -1.26 (-3.89%)
Pre-market: 05:20AM EDT

Biomea Fusion, Inc.

900 Middlefield Road
4th Floor
Redwood City, CA 94063
United States
650 980 9099

Full-time employees75

Key executives

NameTitlePayExercisedYear born
Mr. Thomas Andrew ButlerCo-Founder, Chairman & CEO772.86kN/A1981
Mr. Ramses M. ErdtmannCo-Founder, Pres, COO & Director570.57kN/A1963
Mr. Franco ValleCFO & Principal Accounting Officer251.69kN/A1981
Mr. Heow TanChief Technology & Quality OfficerN/AN/A1959
Ms. Naomi CretcherChief People OfficerN/AN/AN/A
Dr. Thorsten Kirschberg Ph.D.Exec. VP of ChemistryN/AN/A1970
Dr. Stephan Morris M.D.Chief Medical OfficerN/AN/AN/A
Mr. Ravi UpasaniSr. VP of Intellectual PropertyN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Corporate governance

Biomea Fusion, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.